American Origin Unverified This profile is unclaimed and has not been independently reviewed. Claim & get verified

INTERPACE BIOSCIENCES, INC. (IDXG)

$6.50 +20.37% OTC: IDXG · 15-min delayed

PARSIPPANY, New Jersey
Public · OTC: IDXG

Visit website Follow

$38.7MRevenue · FY2025

$24.6MNet income

IDXGOTC

About INTERPACE BIOSCIENCES, INC.

INTERPACE BIOSCIENCES INC

This profile is unclaimed. An authorized representative can claim it free to control the page and activate the embeddable Verified badge.

Company facts

Type: Public · OTC: IDXG
Headquarters: PARSIPPANY, New Jersey
Industry: Medical Devices
Website: Visit site

Registry IDs

Ticker: IDXG OTC
SEC CIK: 1054102
EIN: 222919486
SIC: 3841 Surgical & Medical Instruments & Apparatus

Explore our data studies: the biggest company in every US state · all rankings & reports.

Embed this company’s badge

Show Interpace Biosciences, Inc.’s American-company profile badge on a website — copy this HTML:

<a href="https://americancompanies.com/company/interpace-biosciences-inc/"><img src="https://americancompanies.com/badge/interpace-biosciences-inc.svg" alt="Interpace Biosciences, Inc. — American company profile on americancompanies.com" width="220"></a>

Is this your company?

This profile is unclaimed — any authorized owner can claim it free, control the page, and activate the embeddable Verified badge for their own website.

Claim this profile — free

Track American companies

Create a free account to follow INTERPACE BIOSCIENCES, INC. and get an email when it moves sharply — real market data, 15-minute delayed.

Create free account

Reported figures

Financial summary

Revenue FY2025: $38.7M
Net income: $24.6M
Total assets: $33.8M

Source: SEC EDGAR · updated Jun 7, 2026

OTC: IDXG

$6.50 +20.37%

15-minute delayed · data by Polygon.io

Past year · hover for prices

$4.10 $11.50

52-week range

Open: —
Day range: –
Prev close: —
Volume: —

Interpace Biosciences, Inc. (IDXG) Stock Price

Profitable — net income of $24.6M in FY2025.
Trading 43% below its 52-week high.

Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.

No reviews yet. Be the first to review INTERPACE BIOSCIENCES, INC..

Write a review

Newsroom

News about INTERPACE BIOSCIENCES, INC.

Interpace Biosciences Announces Preliminary Unaudited Third Quarter 2026 Revenue GlobeNewswire Inc. · 2026-10-15 · positive Effective May 2, 2025, Interpace Diagnostics® Will No Longer Accept Specimens for PancraGEN®, a Molecular Diagnostic Test That Assesses Pancreatic Cyst Cancer Risk GlobeNewswire Inc. · 2025-04-24 · negative PancraGEN® Will Continue to be Offered While Interpace Re-evaluates its Previously Announced Re-structuring Plan GlobeNewswire Inc. · 2025-01-27 · positive Effective 02/07/2025, Interpace Diagnostics® to No Longer Offer PancraGEN®, a Molecular Diagnostic Test That Assesses Pancreatic Cyst Cancer Risk GlobeNewswire Inc. · 2025-01-09 · neutral Interpace Biosciences Announces First Quarter 2024 Financial and Business Results GlobeNewswire Inc. · 2024-05-09

News & sentiment via Polygon.io

FAQ

Interpace Biosciences, Inc.: frequently asked questions

Is Interpace Biosciences, Inc. an American company?

Interpace Biosciences, Inc. is a US-based company headquartered in Parsippany, New Jersey, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.

Where is Interpace Biosciences, Inc. headquartered?

Interpace Biosciences, Inc. is headquartered in Parsippany, New Jersey, United States.

Is Interpace Biosciences, Inc. publicly traded?

Yes — Interpace Biosciences, Inc. is a publicly traded company. Its stock trades under the ticker symbol IDXG on the OTC.

What does Interpace Biosciences, Inc. do?

Interpace Biosciences, Inc. is an American Medical Devices company in the Health & Beauty sector.

Explore